Table 3 Clinical characteristics of COVID-19 illness
COVID-19 characteristics | n (%) |
Viral shedding status | |
PCR-positive, n (%) | 95 (81) |
Duration of PCR positivity, days median (range) | 12 (6–80) |
WHO Severity Score | |
1, Asymptomatic | 24 (20) |
2–3, Mild | 52 (44) |
4–5, Moderate | 36 (31) |
>5, Severe | 6 (5) |
Admission to hospital | |
Not hospitalized | 54 (49) |
Admitted with COVID-19-like illness | 33 (29) |
COVID-19 illness during hospitalization | 30 (25) |
Duration of admission, days median (range) | 9 (1–120) |
Complications of COVID-19 | |
Required supplemental oxygen | 27 (23) |
Pneumonia | 29 (25) |
Venous/arterial thromboembolism | 9 (8) |
Admission to intensive therapy unit | 7 (6) |
Need for mechanical ventilation/NIV | 4 (3) |
COVID-19-directed therapy | |
Corticosteroids | 13 (11) |
Anti-IL-6 monoclonal antibody | 3 (3) |
Laboratory investigations, median (IQR) | |
Hematology | |
Hb, g l−1 | 110 (93–128) |
WBC, × 106 l−1 | 5.7 (3.4–8.0) |
N0, × 106 l−1 | 3.8 (2.1– 5.5) |
Plt, × 106 l−1 | 213 (130–299) |
Biochemistry | |
Creatinine, μmol l−1 | 60 (53–71) |
CRP, mg l−1 | 59 (23–134) |
Clinical outcomes and impact | |
Survival | |
Deceased, n (%) | 13 (10) |
Death within 30 d of PCR positivity | 4 (3) |
Primary cause death: | |
Progressive cancer | 11 (9) |
Complications of COVID-19 | 2 (2) |
